Workflow
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
Globenewswire·2025-07-01 11:00

Core Insights - Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as an advisor in business development, aiming to enhance its clinical strategy and business development efforts [1][5] Company Overview - Avacta is a clinical-stage life sciences company focused on developing targeted oncology drugs, utilizing its proprietary pre|CISION platform to deliver potent cancer therapies while minimizing damage to normal tissues [7] Leadership Background - Dr. Liebowitz brings over 30 years of experience in hematology-oncology and drug development, having successfully filed more than 25 Investigational New Drug (IND) applications [2] - Prior to joining Avacta, Dr. Liebowitz held senior positions at Inovio Pharmaceuticals, Xencor, Vaxart, and Amgen, focusing on oncology and immunotherapy [2] - Mr. Bogatyrenko has extensive experience in business development and commercial strategy, having led global drug launches and partnerships at major pharmaceutical companies like Pfizer, Bayer, and Teva [4] Strategic Importance - The appointments of Dr. Liebowitz and Mr. Bogatyrenko are seen as pivotal for Avacta, as they aim to advance the company's clinical development strategy and corporate growth [5]